The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near…
“With multiple potential blockbusters in development, and a track record that proves the company knows how to launch a new drug… [this] stock is probably worth the risk right now,” advises the author of today’s article in regards to the biotech he examines, which, having just launched its first rare disease drug last spring, could receive its fourth new drug…
After being awarded $1.6 billion in funding by the U.S. government as part of its fast-track COVID-19 vaccine program Operation Warp Speed – the largest deal made by the program – shares of Novavax surged 32% in one trading session. On the heels of this surge, do shares of Novavax have more room to run – or is there little…